Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in Neovascular AMD
NCT02461771Phase 1Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Mar 2016
- Modality
- PEGylated Peptides
- Countries
- 2
01
Overview
Phase 1, open-label trial of pegcetacoplan in neovascular age-related macular degeneration (NVAMD) (3 cohorts), sponsored by Apellis Pharmaceuticals. Primary endpoints: Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Number of Dose Limiting Toxicities and 3 more. Started Jan 2015; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02461771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461771.